Serum BCM-IMx Levels in 376 Patients with Non-Malignant Diseases

Daver A. , Lennartz L. , Bellia M.F. , Dalifard I. , Lemieux P. , Page M. . Comparison of a new marker, BCM-EIA, to CA15.3 and MCA for detection and monitoring of breast cancer patients. Tumor Biology 1990; 11: 84.

Allende MaT , Vizoso F. , Fueyo A. , Roiz MC , Lennartz L. , Ruibal A. . Serum BCM levels in patients with non tumoral pathologies: a volume of 25 U/ml can be used as threshold for tumoral activity. Int J Biol Markers 1990; 5: 50–1.

Allende MaT , Vizoso F. , Roiz MC , Fueyo A. , Lennartz L. , Ruibal A. . High BCM seric levels in patients having non breast tumors. First results. Bull Cancer (Paris) 1990; 77: 1031–2.

Blankenstein M.A. . Analytical and clinical experience with the IMx-BCM. Satellite Symposium. BCM-breast cancer mucin-new tumor marker in breast cancer. III International Symposium on Biology and Clinical Usefulness of Tumor Markers. Madrid, September 7th.

Molina R. . BCM in benign and malignant breast pathology. Satellite Symposium. BCM-breast cancer mucin-new tumor marker in breast cancer. III International Symposium on Biology and Clinical Usefulness of Tumor Markers. Madrid, September 7th.

Daver A. . BCM in primary breast cancer patients. Satellite Symposium. BCM-breast cancer mucin-new tumor marker in breast cancer. III International Symposium on Biology and Clinical Usefulness of Tumor Markers. Madrid, September 7th.